Saturday, February 6, 2021
1:00 – 3:00 p.m.
Virtual Meeting via Zoom
Meet Biotech Company Praxis…
and learn about Investigational Drug PRAX-944
presented by Gabriel Belfort M.D., Ph.D. and Lisa Huang, Ph.D.
At this virtual meeting, you will learn about Praxis, a biotechnology company studying an investigational treatment for Essential Tremor. PRAX-944 belongs to a new class of drugs called T-type calcium channel blockers. It has been shown to be effective in animal models of Essential Tremor by blocking calcium channels that are essential to the rhythmic brain activity that causes tremor activity. If PRAX-944 can similarly block T-type calcium channels in patients with ET, it is possible that the abnormal rhythmic activity in the brain – and the subsequent tremors – may improve! Studies with PRAX-944 in ET patients have been initiated. You won’t want to miss this meeting to learn more!
Gabriel Belfort, M.D., Ph.D., is a Senior Medical Director at Praxis and is responsible for the design, conduct, and data analysis of studies in the PRAX-944 Essential Tremor program. He has been in the industry for eight years and with Praxis for two. He received an M.D. and a Ph.D. from Boston University, residency training in neurology from the Beth Israel Deaconess Medical Center, and postdoctoral training from MIT. Gabi was involved in the development of Brexanolone, now FDA approved for the treatment of post-partum depression.
Lisa Huang, Ph.D. is the commercial lead for the PRAX-944 Essential Tremor program. She has been in the industry for eight years, where she founded a number of biotechs, such as Magenta, Gemini Therapeutics, and Q32 Bio Inc. to address diseases with high clinical need. A human geneticist by training, Lisa obtained her PhD Degree from Johns Hopkins.
Inquiries are invited!
Registration is required no later than noon on Wednesday, February 3rd!
To register or request information, email Helen Moser or submit the form below.
The CT essential tremor support group is sponsored by